Cantel Medical Corp. (NYSE:CMD) Director Mark N. Diker sold 7,000 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $98.90, for a total value of $692,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Cantel Medical Corp. (NYSE:CMD) traded down 1.37% on Thursday, hitting $97.68. The stock had a trading volume of 53,274 shares. The firm has a 50-day moving average of $83.65 and a 200 day moving average of $77.53. Cantel Medical Corp. has a 52 week low of $68.19 and a 52 week high of $99.83. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 57.12 and a beta of 1.25.

Cantel Medical Corp. (NYSE:CMD) last released its quarterly earnings data on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $205.50 million during the quarter, compared to analyst estimates of $200.32 million. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. On average, analysts predict that Cantel Medical Corp. will post $2.34 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/05/mark-n-diker-sells-7000-shares-of-cantel-medical-corp-cmd-stock.html.

Several research firms have recently weighed in on CMD. Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical Corp. in a research note on Friday, September 1st. Benchmark Co. downgraded Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Zacks Investment Research downgraded Cantel Medical Corp. from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Sidoti upgraded Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Wednesday, August 2nd. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $91.67.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Cantel Medical Corp. in the second quarter worth about $376,271,000. Vanguard Group Inc. purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $246,860,000. Neuberger Berman Group LLC purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $96,236,000. Dimensional Fund Advisors LP purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $75,756,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $75,715,000. 83.79% of the stock is owned by hedge funds and other institutional investors.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Insider Buying and Selling by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.